What Alvotech (ALVO) Said on Its Q3 Earnings Call
Alvotech (ALVO) reported Q3 revenue down 23% YoY, citing production delays and licensing timing. Adjusted EBITDA rose 15% to $78M. CEO maintained guidance despite delayed approvals. FDA approved manufacturing changes, doubling capacity. Cash fell to $61M due to working capital. Company expects Q4 cash-flow positivity and 2027 EBITDA improvement.
How this was made

The 30-second read
Why it matters
The earnings release highlights operational challenges and a cash crunch, which may trigger short‑term sell pressure.
Market read
Primary earnings disclosure for a small‑cap biotech; relevance driven by revenue decline, cash burn, and manufacturing upgrades.
What to watch
Potential partnership revenue from Lotte Biologics and Fujifilm may improve cash flow beyond the disclosed guidance.
Background
Alvotech is a Nasdaq‑listed biosimilar developer focused on immunology and oncology products.
Ticker impact
Q3 earnings disclosed revenue down 23%, cash down to $61M, and expanded manufacturing capacity with FDA approvals.
likely pressure as the market prices in weaker revenue and liquidity concerns.
The report shows a significant revenue decline and a sharp cash reduction, while guidance remains vague, suggesting short‑term weakness.
Market effects
Biosimilar sector may see heightened scrutiny on cash‑intensive manufacturers.
Icelandic biotech exposure could affect regional biotech sentiment.
Limited to investors in niche biotech and biosimilar space.
Counterpoint
Capacity expansion could enable a turnaround later in 2027, making the stock a long‑term buy despite short‑term pain.
Key entities
- CompanyAlvotech
NASDAQ‑listed biosimilar developer.
- PartnerTeva
Co‑developer of AVT05 biosimilar.


